The group at risk of endometrial hyperplasia are those women using a GLP-1 and also using TD oestrogen (which will be unaffected by the GLP-1 agonist) and an oral progestogen, as the absorption of the progestogen may be reduced while the oestrogen stays the same, leaving the woman with an unbalanced regime and an insufficient amount of progestogen to protect her endometrium from the oestrogen
Stopping smoking was associated with reduced odds of AMD
CEO Brian Lian framed the differentiation as "the only dual agonist molecule with the potential to dose monthly or to allow transition from subcutaneous to oral administration for weight maintenance." Risk: Viking is pre-revenue, with a 2025 net loss of $359.64 million and a cash position that fell from $903 million at the start of 2025 to $706 million at year-end
Surgery can lead to sustainable weight loss and improved metabolic health without the dependency on medications
Key Benefit: Proven fat loss effects, especially in the abdominal region
For elective surgery, both drugs typically require a 1-week hold before the procedure due to gastroparesis risk with general anesthesia
